Daiichi Sankyo Co. Ltd. has submitted a new drug application in Japan for trastuzumab deruxtecan (DS-8201), its HER2-targeting lead antibody-drug conjugate (ADC), for HER2-positive metastatic breast cancer.
The Japanese filing, the first globally in any indication, marks another step towards market for the product, the subject of a huge $6.9bn ex-Japan deal with AstraZeneca PLC in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?